CO6190617A2 - Compuesto carboxamida y su uso como inhibidores de calpaina - Google Patents

Compuesto carboxamida y su uso como inhibidores de calpaina

Info

Publication number
CO6190617A2
CO6190617A2 CO09066778A CO09066778A CO6190617A2 CO 6190617 A2 CO6190617 A2 CO 6190617A2 CO 09066778 A CO09066778 A CO 09066778A CO 09066778 A CO09066778 A CO 09066778A CO 6190617 A2 CO6190617 A2 CO 6190617A2
Authority
CO
Colombia
Prior art keywords
alkyl
radicals
aryl
cycloalkyl
last
Prior art date
Application number
CO09066778A
Other languages
English (en)
Inventor
Andreas Kling
Wilfried Hornberger
Helmut Mack
Achim Moeller
Volker Nimmrich
Dietmar Seemann
Wilfried Lubisch
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39226751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6190617(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of CO6190617A2 publication Critical patent/CO6190617A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

1.- Un compuesto carboxamida de la fórmula Ien el cual R1 es hidrógeno, C1-C10-alquilo, C2-C10-alquenilo, C2-C10-alquinilo, donde los últimos 3 radicales mencionados pueden estar parcial o totalmente halogenados y/o tener 1, 2 o 3 sustituyentes R1a, C3-C7-cicloalquilo, C3-C7-cicloalquil-C1-C4-alquilo, donde un grupo CH2 en la porción cicloalquilo de los últimos dos radicales mencionados se puede reemplazar con O, NH, o S, o dos átomos de C adyacentes pueden formar un enlace doble, donde la porción cicloalquilo puede tener además 1, 2, 3 o 4 radicales R1b, arilo, hetarilo, aril-C1-C6-alquilo, aril-C2-C6-alquenilo, hetaril-C1-C4-alquilo o hetaril-C2-C6-alquenilo, donde arilo y hetarilo en los últimos 6 radicales mencionados puede no estar sustituido o tener 1, 2, 3 o 4 radicales R1c idénticos o diferentes; dondeR1a se selecciona en forma independiente uno del otro entre OH, SH, COOH, CN, OCH2COOH, C1-C6-alcoxi, C1-C6-haloalcoxi, C3-C7-cicloalquiloxi, C1-C6-alquiltio, C1-C6-haloalquiltio, COORa1, CONRa2Ra3, SO2NRa2Ra3, -NRa2SO2-Ra4, NRa2-CO-Ra5, SO2-Ra4, NRa6Ra7, R1b se selecciona en forma independiente uno del otro entre OH, SH, COOH, CN, OCH2COOH, halógeno, C1-C6-alquilo, fenilo el cual tiene opcionalmente 1, 2 o 3 sustituyentes R1d, o C1-C6-alquilo, C1-C6-alcoxi, C1-C6-alquiltio, donde las porciones alquilo en los últimos 3 sustituyentes mencionados pueden estar parcial o totalmente halogenados y/o tener 1, 2 o 3 sustituyentes R1a, COORb1, CONRb2Rb3, SO2NRb2Rb3, NRb2SO2Rb4, NRb2-CO-Rb5, SO2-Rb4, NRb6Rb7, donde además dos radicales R1b pueden formar juntos un grupo C1-C4-alquenilo, o 2 radicales R1b unidos a átomos de C adyacentes de cicloalquilo pueden formar junto con los átomos de carbono a los cuales se encuentran unidos un anillo benceno, R1c se selecciona en forma independiente uno del otro entre OH, SH, halógeno, NO2, NH2, CN, CF3, CHF2, CH2F, O-CF3, O-CHF2, O-CH2F, COOH, OCH2COOH, C1-C6-alquilo, C1-C6-alcoxi, C1-C6-alcoxi-C1-C4-alquilo, C1-C6-alquiltio, donde las porciones alquilo en los últimos 4 sustituyentes mencionados pueden estar parcial o totalmente halogenados y/o tener 1, 2 o 3 sustituyentes R1a, C3-C7-cicloalquilo, C3-C7-cicloalquil-C1-C4-alquilo, C3-C7-cicloalquiloxi, donde la porción cicloalquilo de los últimos tres radicales mencionados puede tener 1, 2, 3 o 4 radicales R1b, arilo, hetarilo, O-arilo, O-CH2-arilo, ...
CO09066778A 2006-12-29 2009-06-26 Compuesto carboxamida y su uso como inhibidores de calpaina CO6190617A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127369 2006-12-29

Publications (1)

Publication Number Publication Date
CO6190617A2 true CO6190617A2 (es) 2010-08-19

Family

ID=39226751

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09066778A CO6190617A2 (es) 2006-12-29 2009-06-26 Compuesto carboxamida y su uso como inhibidores de calpaina

Country Status (29)

Country Link
US (4) US8436034B2 (es)
EP (2) EP2439205B1 (es)
JP (1) JP5295976B2 (es)
KR (3) KR101578674B1 (es)
CN (1) CN101616908B (es)
AR (2) AR064693A1 (es)
AT (1) ATE544758T1 (es)
AU (1) AU2007341232B2 (es)
BR (1) BRPI0721298A2 (es)
CA (1) CA2673580C (es)
CL (1) CL2007003879A1 (es)
CO (1) CO6190617A2 (es)
DK (1) DK2439205T3 (es)
EC (1) ECSP099476A (es)
ES (2) ES2381879T3 (es)
GT (1) GT200900186A (es)
HK (1) HK1138833A1 (es)
IL (2) IL199447A (es)
MX (1) MX2009007050A (es)
MY (1) MY147780A (es)
NZ (2) NZ599860A (es)
PE (1) PE20081609A1 (es)
PL (1) PL2439205T3 (es)
PT (1) PT2439205E (es)
RU (2) RU2485114C2 (es)
TW (1) TWI405571B (es)
UA (1) UA100501C2 (es)
UY (1) UY30850A1 (es)
WO (1) WO2008080969A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673580C (en) * 2006-12-29 2015-11-24 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
TWI453019B (zh) 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物
US20110190365A1 (en) * 2008-08-14 2011-08-04 Bayer Crop Science Ag Insecticidal 4-phenyl-1H-pyrazoles
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶(calpain)抑制劑之用途
US8236798B2 (en) 2009-05-07 2012-08-07 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
PE20121025A1 (es) * 2009-09-28 2012-08-06 Hoffmann La Roche Compuestos de benzoxazepina como inhibidores de la p13k
US9051304B2 (en) 2009-12-22 2015-06-09 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
US8598211B2 (en) * 2009-12-22 2013-12-03 Abbvie Inc. Carboxamide compounds and their use as calpain inhibitors IV
GB2505572B (en) 2010-04-30 2014-08-06 Abbott Cardiovascular Systems Catheter system providing step reduction for postconditioning
US9062027B2 (en) 2010-12-09 2015-06-23 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
AR085013A1 (es) * 2011-01-26 2013-08-07 Sanofi Aventis Derivados de acido 3-heteroaroilamino-propionico sustituidos y su uso como sustancias farmaceuticas
WO2013126283A1 (en) 2012-02-20 2013-08-29 E. I. Du Pont De Nemours And Company Fungicidal pyrazoles
RU2014144285A (ru) 2012-04-03 2016-05-27 Эббви Дойчланд Гмбх Унд Ко. Кг Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина v
PT2978752T (pt) 2013-03-29 2018-03-09 Takeda Pharmaceuticals Co Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e o seu uso como inibidores de phd
CA2920815C (en) * 2013-08-14 2021-09-21 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
CN108463109B (zh) 2015-12-22 2022-04-29 先正达参股股份有限公司 杀有害生物活性吡唑衍生物
CN108164446A (zh) * 2016-01-26 2018-06-15 绍兴瑞康生物科技有限公司 一种羧酰胺类化合物及其制备方法和应用
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
KR20190063473A (ko) 2016-09-28 2019-06-07 블레이드 테라퓨틱스, 인크. 칼페인 조정자 및 그 치료학적 용도
JP7183270B2 (ja) * 2017-08-16 2022-12-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 新規化合物
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
SI3716952T1 (sl) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Limited Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina
MX2020010033A (es) * 2018-03-28 2020-10-14 Blade Therapeutics Inc Moduladores calpaina y usos terapeuticos de los mismos.
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH21213A (en) 1984-10-26 1987-08-21 Fujisawa Pharmaceutical Co Benzene- and pyrazole- fused heterocyclic compound and pharmaceutical composition comprising the same
US4826835A (en) 1985-10-23 1989-05-02 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
US4743608A (en) 1986-07-15 1988-05-10 Rorer Pharmaceutical Corporation Pyridone-pyridyl-imidazolyl and triazolyl compounds and their use as cardiotonic agents
US4888352A (en) 1989-03-22 1989-12-19 Sterling Drug Inc. 3,4, or 5-aryl-1H-pyrazole-1-alkanamides as antiarrhythmic agents, compositions and use
GB9412603D0 (en) * 1994-06-23 1994-08-10 Sandoz Ltd Organic compounds
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
JP4099237B2 (ja) 1996-12-11 2008-06-11 アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト カルパインインヒビターとしてのケトベンズアミド
US6127556A (en) 1996-12-31 2000-10-03 G. D. Searle & Co. Epoxide formation by continuous in-situ synthesis process
US6083944A (en) 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
ID26403A (id) 1998-04-20 2000-12-21 Basf Ag Amida baru yang tersubstitusi, pembuatan dan penggunaannya
AU3818799A (en) 1998-04-20 1999-11-08 Basf Aktiengesellschaft Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
DE59914996D1 (en) * 1998-04-20 2009-05-14 Abbott Gmbh & Co Kg Heterocyclisch substituierte amide als calpainhemmer
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
EP1080074B1 (de) * 1998-05-25 2006-11-08 Abbott GmbH & Co. KG Heterocyclische substituierte Amide, deren Herstellung und Verwendung
AR018915A1 (es) * 1998-06-24 2001-12-12 Smithkline Beecham Corp Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
WO2001068645A2 (en) * 2000-03-15 2001-09-20 Axys Pharmaceuticals, Inc. N-cyanomethylcarboxamides and their use as protease inhibitors
JP2001261675A (ja) 2000-03-21 2001-09-26 Mitsui Chemicals Inc ピラゾリン誘導体またはテトラヒドロピリダジン誘導体を含有する医薬
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE10114762A1 (de) 2001-03-26 2002-10-02 Knoll Gmbh Verwendung von Cysteinprotease-Inhibitoren
PT1482924E (pt) * 2002-03-05 2008-08-27 Axys Pharm Inc Inibidores de proteases da cisteína catepsina
EP1610263A1 (en) 2004-06-18 2005-12-28 Sicpa Holding S.A. Item carrying at least two data storage elements
WO2006080439A1 (ja) 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
CA2673580C (en) * 2006-12-29 2015-11-24 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
TWI453019B (zh) * 2007-12-28 2014-09-21 Abbvie Deutschland 甲醯胺化合物

Also Published As

Publication number Publication date
ES2381879T3 (es) 2012-06-01
IL231463A0 (en) 2014-04-30
KR20090097205A (ko) 2009-09-15
US7728012B2 (en) 2010-06-01
US20100298326A1 (en) 2010-11-25
AR064693A1 (es) 2009-04-22
EP2121653B1 (en) 2012-02-08
IL199447A (en) 2014-04-30
US20080234330A1 (en) 2008-09-25
EP2439205A1 (en) 2012-04-11
EP2121653A1 (en) 2009-11-25
KR20150090282A (ko) 2015-08-05
RU2485114C2 (ru) 2013-06-20
PT2439205E (pt) 2015-07-16
US20080234329A1 (en) 2008-09-25
CA2673580A1 (en) 2008-07-10
MY147780A (en) 2013-01-31
GT200900186A (es) 2012-03-16
US8436034B2 (en) 2013-05-07
AR077477A2 (es) 2011-08-31
PL2439205T3 (pl) 2015-08-31
KR20150090281A (ko) 2015-08-05
UA100501C2 (uk) 2013-01-10
ECSP099476A (es) 2009-07-31
JP2010514738A (ja) 2010-05-06
CL2007003879A1 (es) 2008-07-04
NZ577719A (en) 2012-06-29
AU2007341232A1 (en) 2008-07-10
TWI405571B (zh) 2013-08-21
EP2439205B1 (en) 2015-03-11
HK1138833A1 (en) 2010-09-03
IL231463A (en) 2016-02-29
US7799809B2 (en) 2010-09-21
US20130245003A1 (en) 2013-09-19
MX2009007050A (es) 2009-09-23
UY30850A1 (es) 2008-07-31
RU2009129119A (ru) 2011-02-10
ATE544758T1 (de) 2012-02-15
NZ599860A (en) 2013-09-27
DK2439205T3 (da) 2015-06-22
PE20081609A1 (es) 2008-11-12
CN101616908A (zh) 2009-12-30
TW200845979A (en) 2008-12-01
KR101578674B1 (ko) 2015-12-18
US9139557B2 (en) 2015-09-22
JP5295976B2 (ja) 2013-09-18
WO2008080969A1 (en) 2008-07-10
ES2536626T3 (es) 2015-05-27
CN101616908B (zh) 2014-09-10
CA2673580C (en) 2015-11-24
BRPI0721298A2 (pt) 2014-03-25
RU2013104459A (ru) 2014-08-10
AU2007341232B2 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CO6190617A2 (es) Compuesto carboxamida y su uso como inhibidores de calpaina
ES2515194T3 (es) Derivados de pirrolidina
ECSP11010770A (es) Compuesto heterocíclico y su uso
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
DE112006001311A5 (de) Metallgewebe, Anordnung eines Metallgewebes und Verfahren zum Illuminieren
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
EA200900441A1 (ru) Способы и интермедиаты для получения ингибиторов интегразы
CO6170406A2 (es) Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas
RS54473B1 (en) INTERMEDIATES FOR OBTAINING MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS
DE602008000754D1 (de) Tropanverbindungen
CO6362009A2 (es) Derivados de morfolinopurina
CO6260014A2 (es) N-alquinil-2-alquiltio-2-(heteroariloxi sutituido) - alquilamidas utiles como fungicidas
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
MX2016003196A (es) Derivados antibacterianos del 2h-indazol.
MX2016011380A (es) Derivados de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona y su uso como agentes antibacterianos.
DE602007000505D1 (de) Pulverzusammensetzungen mit Beta-Hydroxyalkylamiden von der Ringöffnung saurer Verbindungen
AR066268A1 (es) Compuesto de imidazol sustituido y su uso
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
AR083723A1 (es) Inhibidores del virus de la hepatitis c
CO6270356A2 (es) Derivados de sulfonato de dioxoantraceno
DK1941613T3 (da) Komparator med resonante tunneling dioder
RU2007115301A (ru) Средства, обладающие антирадикальной, гемореологической, антитромбоцитарной и антитромбогенной активностью
EA201001651A1 (ru) Штукатурный маяк
ECSP12011794A (es) Colorante reactivo

Legal Events

Date Code Title Description
FG Application granted